Abstract: The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
Type:
Grant
Filed:
September 7, 2022
Date of Patent:
November 14, 2023
Assignee:
River 3 Renal Corp.
Inventors:
He Hongyan, Jiang Siyi, Urs Schwitter, Pascal Jean Claude Dott, Ralph Diodone, Nicole Wyttenbach, Olaf Grassmann
Abstract: The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
Type:
Application
Filed:
September 7, 2022
Publication date:
August 3, 2023
Applicants:
River 3 Renal Corp., Hoffmann-La Roche Inc.
Inventors:
He Hongyan, Jiang Siyi, Urs Schwitter, Pascal Jean Claude Dott, Ralph Diodone, Nicole Wyttenbach, Olaf Grassmann